PatientsVille.com Logo

Coronary and Amlodipine

PatientsVille

Coronary Symptoms and Causes

Coronary artery disease (CAD) is the most common type of heart disease. It is the leading cause of death in the United States in both men and women.

CAD happens when the arteries that supply blood to heart muscle become hardened and narrowed. This is due to the buildup of cholesterol and other material, called plaque, on their inner walls. This buildup is called atherosclerosis. As it grows, less blood can flow through the arteries. As a result, the heart muscle can't get the blood or oxygen it needs. This can lead to chest pain (angina) or a heart attack. Most heart attacks happen when a blood clot suddenly cuts off the hearts' blood supply, causing permanent heart damage.

Over time, CAD can also weaken the heart muscle and contribute to heart failure and arrhythmias. Heart failure means the heart can't pump blood well to the rest of the body. Arrhythmias are changes in the normal beating rhythm of the heart.

NIH: National Heart, Lung, and Blood Institute

Check out the latest treatments for coronary

coronary treatment research studies

Amlodipine clinical trials, surveys and public health registries


Find Drug Side Effect reports



Amlodipine Side Effects

Completed Suicide (594)
Hypotension (565)
Dizziness (403)
Overdose (356)
Oedema Peripheral (348)
Fatigue (321)
Nausea (309)
Headache (306)
Toxicity To Various Agents (299)
Dyspnoea (277)
Renal Failure Acute (274)
Rash (249)
Blood Pressure Increased (228)
Hypertension (218)
Malaise (216)
Vomiting (213)
Suicide Attempt (212)
Shock (212)
Intentional Overdose (205)
Asthenia (183)
Metabolic Acidosis (146)
Diarrhoea (143)
Joint Swelling (142)
Bradycardia (129)
Arthralgia (123)
Fall (122)
Pain (116)
Myalgia (116)
Syncope (114)
Palpitations (113)
Pruritus (108)
Cough (108)
Feeling Abnormal (107)
Somnolence (105)
Product Substitution Issue (105)
Muscle Spasms (105)
Loss Of Consciousness (105)
Pain In Extremity (102)
Death (96)
Anxiety (95)
Chest Pain (94)
Blood Pressure Inadequately Controlled (94)
Confusional State (91)
Renal Failure (90)
Condition Aggravated (88)
Angioedema (87)
Lethargy (87)
Insomnia (84)
Abdominal Pain (84)
Pneumonia (83)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

5 months suffering difficulty in breathing through the noes after taking more than 1 year ago, .Pigmentation starts to show on both leg front leg and at the ankle.My BP is 130/82 but is always fluatuate sometime below 120/70.My doctor asked me to ta

:( alas, tried it for one month and not good!. main problems, bloating, abdominal discomfort, reflux/heartburn,[had to try sleep sitting up], symptoms went on stopping, returned on restart, did lower my BP but too high a cost!.

After 2 months taking Amlopipine i developed double vision, went away when I reduced dosage, any one have anything similar.

After NGOPlasti He has alergic problem i.e. white spot in the skin and sensetation in the resperatory system

After taking Amlodipine 10mg for a year or so, can it then cause itching on the upper body; arms, back, and ribs?

After taking Amlodipine for 300 years, my d!ck fell off

Amlodpine is a dihydropyridine group Ca channel blocker usually prescribed to controll hypertension (Males) or prinz metal angina (Females) trade names Norvasac Quvasac ..... Ca channels are universally present in our b

Any advice please? Legs & ankles have swollen up terribly. Am I safe to stop them for a while. Weekend and can't get to the Doctor.

Erectical dysfunction since I started taking it in 2007

From the left side of my nose to theupper left side of my jaw more like my gums hurt

54y/o, WM, Status post quadruple coronary artery bypass graft surgery(10 months ago). Surgery went well, only complication was a pretty large left pleural effusion requiring chest tube placement. Resolved well, no further problems

Hello, I am suffering of coronary insufficiency and atrial fibrilation.I had a myocardial infarction before 6 years.Itake amiodarone and atenolol.Can i use pradaxa??

I am taking Betaloc 50 g.since last 11 years for treatment of coronary artery disaese with Hypertension.It has done nice to me without any problem. Since it is cardioseective, it has no adverse effect on respiratory system or any side effecct related

I have Coronary heart disease i.e. Severe concentric hypertrophy of left Ventricle. I have done coronary angiography but there is no block. Heart specialist has prescribe d me Trimetazidfine 35 mg two times daily.I have been also talking nevivolol 5

Vasocardol was prescribed for me following an identified partial blockage in a coronary artery (LAD). I was initially OVERDOSED (240mg). My normal resting pulse of 52 went down into the 40s. I was light-headed. My pulse also became so uneven that I

Coronary Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Not yet recruiting CKD-330 Drug-Drug Interaction Study (Amlodipine)
Condition: Hypertension
Interventions: Drug: Amlodipine 10mg;   Drug: Amlodipine 10mg/Candesartan 32mg
Outcome Measures: AUCτ,ss of Amlodipine;   Cmax,ss of Amlodipine;   Tmax,ss of Amlodipine
2 Recruiting Relative Bioavailability Study of One Amlodipine 10mg Tablet and One Rosuvastatin 20mg Tablet to Two Fixed Dose Combinations of Amlodipine (10mg) and Rosuvastatin (20mg) in Healthy Subjects Under Fasting Conditions
Condition: Hypertension
Interventions: Drug: Amlodipine+Rosuvastatin;   Drug: GSK3074477 FDC - 1;   Drug: GSK3074477 FDC - 2
Outcome Measures: Plasma pharmacokinetics (PK) parameters of Amlodipine and rosuvastatin following single dose administration;   Additional PK parameters of Amlodipine and rosuvastatin following single dose administration;   Safety as assessed by adverse events;   Safety as assessed by vital signs;   Safety as assessed by clinical laboratory safety data;   Safety as assessed by Electrocardiogram (ECG) parameters
3 Not yet recruiting Study of the Efficacy and Safety of LCZ696 Alone and in Combination With Amlodipine in Patients With Hypertension
Condition: Hypertension
Interventions: Drug: LCZ696;   Drug: Amlodipine;   Drug: LCZ696 and Amlodipine combination;   Drug: Placebo
Outcome Measures: Change from baseline in mean sitting systolic blood pressure (msSBP) of LCZ696 monotherapy compared to placebo;   Change from baseline in mean sitting systolic blood pressure (msSBP) of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone.;   Change from baseline in mean sitting Diastolic Blood Pressure (msDBP) of LCZ696 monotherapy compared to placebo;   Change from baseline in mean sitting Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in pulse pressure;   Change from baseline in mean 24-hour ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean 24-hour ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in trough to peak ratio of mean 24-hour ambulatory Systolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in trough to peak ratio of mean 24-hour ambulatory Diastolic Blood Pressure of LCZ696 monotherapy compared to placebo;   Change from baseline in mean 24-hour ambulatory Systolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean 24-hour ambulatory Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Systolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean daytime ( > 6am and ≤ 10 pm) ambulatory Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Systolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Change from baseline in mean nighttime (> 10 pm and ≤ 6 am) ambulatory Diastolic Blood Pressure of the combination of LCZ696 and Amlodipine compared to LCZ696 and Amlodipine alone;   Percentage of patients achieving msSBP <140 mmHg and msDBP <90 mmHg;   Percentage of patients achieving msSBP <140 mmHg or a reduction ≥20 mmHg from baseline;   Percentage of patients achieving msDBP <90 mmHg or a reduction ≥10 mmHg from baseline;   Number of patients reporting adverse events
4 Not yet recruiting Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension
Condition: Hypertension
Interventions: Drug: Bisoprolol/Amlodipine (Bisoprolol sub-group A);   Drug: Bisoprolol/Amlodipine (Bisoprolol sub-group B);   Drug: Bisoprolol/Amlodipine (Amlodipine sub-group A);   Drug: Bisoprolol/Amlodipine (Amlodipine sub-group B)
Outcome Measures: Mean reduction of systolic blood pressure (SBP) after 18 weeks of treatment from Baseline (latest SBP before study treatment);   Change from Baseline (latest diastolic blood pressure [DBP] before study treatment) in DBP after 18 weeks of treatment;   Percentage of subjects with controlled blood pressure under different dosages of after study treatment;   Change from Baseline (latest heart rate [HR] before study treatment) in HR after 18 weeks treatment;   Number of subjects with adverse events (AEs)
5 Not yet recruiting Bedtime Administration of Amlodipine Versus Lisinopril
Condition: Hypertension
Intervention: Drug: Amlodipine
Outcome Measures: Change in mean sleep-time systolic blood pressure after addition of a bedtime dose of Amlodipine versus lisinopril;   Changes in mean sleep-time diastolic, awake systolic and diastolic blood pressures, including comparison of % achieving target BP;   Impact of individual medications on sleep-time blood pressure drop (dipping status);   Association of baseline renin levels to sleep-time blood pressure drop;   Association of baseline renin levels with response to Amlodipine versus lisinopril;   Association of baseline dipping status with response to Amlodipine versus lisinopril;   Association of age and response to Amlodipine versus lisinopril
6 Recruiting Amlodipine for Myocardial Iron in Thalassemia
Condition: Thalassemia
Interventions: Drug: Deferasirox or Deferoxamine or Combination (Deferoxamine and Deferiprone);   Drug: Amlodipine
Outcome Measures: Efficacy of Amlodipine in retarding rate of myocardial iron deposition (Assessed by change in T2* times);   Effect of Amlodipine therapy on left ventricular size, systolic and diastolic function;   Efficacy of Amlodipine in retarding liver iron content (mg/g);   Adverse effects of Amlodipine therapy
7 Recruiting Efficacy of Amlodipine-Folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
Condition: Essential Hypertension
Interventions: Drug: Amlodipine-FA tablet,low dose group;   Drug: Amlodipine-FA tablet,high dose group;   Drug: Amlodipine
Outcome Measures: Combined effective rate of blood pressure and plasma homocysteine reduction;   Blood pressure reduction or plasma homocysteine reduction
8 Recruiting Efficacy of Amlodipine-folic Acid Tablets on Reduction of Blood Pressure and Plasma Homocysteine
Condition: Essential Hypertension
Interventions: Drug: Amlodipine;   Drug: Amlodipine-FA tablet, low dose group;   Drug: Amlodipine-FA tablet ,high dose group
Outcome Measures: Combined effective rate of blood pressure and plasma homocysteine reduction;   Blood pressure reduction or plasma homocysteine reduction
9 Recruiting Amlodipine Plus/Minus Atorvastatin for Protection of Arteries
Condition: Arterial and Arteriolar Disorders
Interventions: Drug: Amlodipine plus atorvastatin (Caduet);   Drug: Amlodipine (Norvasc)
Outcome Measures: flow-mediated dilation (FMD);   pulse wave velocity (cf-PWV, ba-PWV);   liver function;   ankle-brachial index (ABI);   augmentation index (AIx);   carotid intima-media thickness (IMT);   cholesterol level
10 Recruiting DMTA07 Combine With Amlodipine Treatment in Patients With Hypertension
Condition: Hypertension
Interventions: Drug: AM 5 + DM 0;   Drug: AM 5 + DM 2.5;   Drug: AM 5 + DM 7.5;   Drug: AM 5 + DM 30
Outcome Measures: *SBP reduction=SBP each visit- SBPvisit2;   The secondary objectives of the study include: Efficacy/Safety
11 Recruiting A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
Condition: Essential Hypertension
Interventions: Drug: Amlodipine 5mg;   Drug: Amlodipine 10mg;   Drug: Candesartan Cilexetil 8mg;   Drug: Candesartan cilexetil 16mg
Outcome Measures: Change in sitting Diastolic Blood Pressure (siDBP) at week 8 compared to baseline;   Change in sitting Systolic Blood Pressure (siSBP) at week 4 and 8;   Change in siDBP at week 4;   Proportion of patients achieving ΔsiDBP > 10 mmHg and ΔsiSBP < 20 mmHg after 8 weeks;   Proportion of patients achieving siDBP < 90 mmHg and siSBP < 120 mmHg after 8 weeks
12 Recruiting Comparision of Blood Pressure Variability Between Amlodipine and Losartan
Condition: Hypertension
Interventions: Drug: Amlodipine;   Drug: Losartan
Outcome Measures: SD of visit-to-visit systolic blood pressure variability;   Central systolic blood pressure;   Augmentation index of central blood pressure;   Standard deviation of within-visit systolic blood pressure variability;   Coefficient of variation of visit-to-visit systolic blood pressure variability;   Variation independent of the mean of visit-to-visit systolic blood pressure variability;   24-h ambulatory blood pressure monitoring;   Home systolic blood pressure
13 Not yet recruiting Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
Condition: Hypertension
Interventions: Drug: TELMINUVO Tab. (80/2.5mg);   Drug: TELMINUVO Tab. (80/5mg);   Drug: S-Amlodipine 2.5mg;   Drug: S-Amlodipine 5mg
Outcome Measures: Mean Sitting Systolic Blood Pressure (MSSBP);   Mean Sitting Diastolic Blood Pressure (MSDBP);   Control Rate;   Response Rate
14 Recruiting Drug-drug Interaction Study (Telmisartan, Amlodipine, Chlorthalidone)
Condition: Hypertension
Interventions: Drug: Telmisartan;   Drug: Amlodipine;   Drug: Chlorthalidone
Outcome Measures: AUCt ss, Cmax ss of telmisartan/Amlodipine/chlorthalidone;   Cmin ss, tmax ss, t1/2 of telmisartan/Amlodipine/chlorthalidone
15 Unknown  A Pilot Study Exploring Efficacy and Safety of Amlodipine in the Stented Angina Patients
Condition: Coronary Artery Disease
Interventions: Drug: Placebo;   Drug: Amlodipine
Outcome Measures: Exercise capacity;   Sublingual Nitrate;   Biomarkers
16 Recruiting Fimasartan/Amlodipine Combination Phase III
Condition: Essential Hypertension
Interventions: Drug: Fimasartan and Amlodipine;   Drug: Fimasartan
Outcome Measures: Change of Sitting Systolic Blood Pressure(SiSBP) at week 8 of Investigational Product(IP) Administration from the Baseline;   Change of Sitting Systolic Blood Pressure(SiSBP) at week 4 of Investigational Product(IP) Administration from the Baseline;   Changes of Sitting Diastolic Blood Pressure(SiDBP) at week 4 and 8 of Investigational Product(IP) Administration from the Baseline;   Response rate of the Blood Pressure at week 8 of Investigational Product(IP) Administration;   The Normalization ratio of Blood Pressure at week 8 of Investigational Product(IP) Administration
17 Recruiting Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity
Condition: Coronary Artery Disease
Interventions: Drug: Ranolazine;   Drug: Amlodipine
Outcome Measures: Assessment of platelet reaction units;   Frequency of high platelet reactivity
18 Recruiting A Randomized, Double-Blind, Placebo-Controlled, 3x3 Factorial Design, Phase II Study to Evaluate the Antihypertensive Efficacy and Safety of Combination of Fimasartan and Amlodipine in Patients With Essential Hypertension
Condition: Hypertension
Intervention: Drug: Fimasartan , Amlodipine, Placebo
Outcome Measures: Sitting Diastolic Blood Pressure;   Sitting Systolic Blood Pressure;   Responder ratio
19 Unknown  Amlodipine in the Prevention and Treatment of Iron Overload in Patients With Thalassemia Major
Conditions: Thalassemia;   Iron Overload
Intervention: Drug: Amlodipine
Outcome Measures: Myocardial T2* values (msec);   Liver T2* values (msec);   Serum ferritin levels;   left ventricle volumes and function
20 Recruiting Intermittent Hypoxia 2: Cardiovascular and Metabolism
Conditions: Hypoxia;   Sleep Apnea;   Obstructive Sleep Apnea
Interventions: Drug: Placebo;   Drug: Valsartan;   Drug: Amlodipine
Outcome Measures: Change in sympathetic activity;   Measure of adrenergic, inflammatory and metabolic markers in adipose tissues by chronic intermittent hypoxia versus placebo in healthy nonobese subjects.;   Measure variations in parameters of inflammation in adipose tissue by chronic intermittent hypoxia versus placebo in healthy nonobese subjects.;   Measure of metabolic aspects of the OGTT test.;   Measure the activation of systemic inflammation by chronic HI versus placebo in healthy nonobese subjects. The systemic inflammation will be assessed in non-stress and during the OGTT.;   Assessing markers implicated in the pathophysiology of chronic metabolic diseases after HI versus placebo in healthy nonobese subjects during OGTT.;   Change in vascular responsivness;   Change in Sympathetic and vascular determinant of Blood pressure